logo
Windsor symphony director who traveled for stem cell transplant lauds new Windsor hospital program

Windsor symphony director who traveled for stem cell transplant lauds new Windsor hospital program

Yahoo12-07-2025
The longtime music director of the Windsor Symphony Orchestra says his recent battle with a recurrence of non-Hodgkin lymphoma would've been easier if he could've received a stem-cell transplant in Windsor instead of London — something that is now possible for some patients thanks to a new program at the Windsor Regional Hospital.
Maestro Robert Franz experienced a recurrence in February, around five months before the hospital announced the launch of its autologuous stem cell transplant program.
"It's not easy as a sick person when you're not feeling good, and you're in the middle of chemo to be traveling back and forth two hours," Franz said.
"Some people have to go to Hamilton, which is, of course, twice as far."
Franz had to make the trip three or four times, he said.
Autologous, or auto stem cell transplants, involve a patient's own stem cells being collected and then reinfused back into their body following intensive chemotherapy or radiation, the hospital said in a news release Monday when it announced the program.
"This is a major step forward in offering comprehensive transplant services right here in Windsor-Essex," the release said.
Windsor hospital aiming to do 30 transplants per year
"Prior to this, patients had to travel significant distances to access specialized centres outside the region, resulting in logistical challenges, increased stress for patients and families and potential disruptions to continuity of care."
The hospital's initial roll-out of the program will focus on patients with multiple myeloma, it said.
Its goal is to provide transplants to 30 patients per year, and the first procedure was scheduled to take place July 8.
Franz was first diagnosed with Stage 4 non-Hodgkin lymphoma in 2021.
LISTEN | Robert Franz on his battle with cancer
He underwent intensive chemotherapy, and doctors told him if the cancer stayed away for three years, it likely wouldn't return.
But in February, he want to his doctor with a suspected gall bladder issue and learned that the cancer was back.
"The good news was it came back very localized," he said, "not throughout my body like it was the first time."
The treatment for a recurrence involves more chemotherapy and a stem cell transplant, he added.
"It's just incredible the things that they can do," he said.
Franz is still awaiting a PET scan to see if the process eradicated all the cancer.
"That's the hope and that's the desire," he said, "and ... we're going to wait and see."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Raynaud Phenomenon Tied to Elevated Cardiovascular Risk
Raynaud Phenomenon Tied to Elevated Cardiovascular Risk

Medscape

time15 minutes ago

  • Medscape

Raynaud Phenomenon Tied to Elevated Cardiovascular Risk

TOPLINE: Individuals with Raynaud phenomenon without underlying systemic autoimmune rheumatic diseases had higher risks for major adverse cardiovascular events (MACE) and venous thromboembolism than did a comparator group with irritable bowel syndrome (IBS), regardless of age. METHODOLOGY: Researchers conducted a retrospective cohort study to examine whether individuals with Raynaud phenomenon experienced cardiovascular outcomes more frequently than those without the condition. They included 30,088 individuals younger than 45 years and 60,145 aged 45 years or older with Raynaud phenomenon without systemic autoimmune rheumatic diseases , identified from electronic health records of centers in North America between March 2005 and March 2025. An equal number of propensity score-matched individuals with IBS were assigned as comparators to both age categories. The researchers chose IBS as a comparator group because, like Reynaud phenomenon, it is common in younger and female individuals. In addition, it is not known to be associated with adverse cardiovascular outcomes. Co-primary outcomes were MACE and venous thromboembolism, evaluated over mean follow-up durations of 4.4-4.9 years across groups. TAKEAWAY: Among individuals younger than 45 years, those with Raynaud phenomenon had higher risks for MACE (hazard ratio [HR], 1.23; 95% CI, 1.07-1.42) and venous thromboembolism (HR, 1.32; 95% CI, 1.20-1.46) than did those with IBS. Similar results were observed among individuals aged 45 years or older, where those with Raynaud phenomenon had higher risks for MACE (HR, 1.17; 95% CI, 1.13-1.20) and venous thromboembolism (HR, 1.20; 95% CI, 1.14-1.26) than those with IBS. Individuals with Raynaud phenomenon had higher risks for secondary outcomes such as stroke, any cardiovascular disease, and pulmonary embolism noted in both age categories. IN PRACTICE: '[This] data substantiates several previous reports of an increased risk of CVD [cardiovascular disease] in individuals with RP [Raynaud phenomenon], and provides further supporting evidence of a similar risk of VTE [venous thromboembolism],' the authors of the study wrote. 'Taken together our findings lend further support to suggest that RP (in the absence of any secondary SARD [systemic autoimmune rheumatic disease]) could be a manifestation of subclinical CVD. Of course, this requires further confirmation including prospective studies,' they added. SOURCE: This study was led by Michael Hughes, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom. It was published online on August 5, 2025, in Seminars in Arthritis and Rheumatism. LIMITATIONS: Diagnostic codes were used for identifying the conditions; however, misclassification bias may be possible. Details such as digital ischemic episodes were not available for individuals with Raynaud phenomenon and age of onset and family history were not assessed. Many oral drug treatments for Raynaud phenomenon are vasodilators also used for systemic hypertension; hence, the primary indication was unclear. DISCLOSURES: One author reported receiving support from the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Another author reported receiving support from NIHR Clinical Lectureship, and working at centers supported by Versus Arthritis and NIHR Manchester Biomedical Research Centre. Two authors reported receiving research funding, speaker fees, honoraria, and consultancy fees and having other financial ties with multiple companies including Janssen, Sanofi, and Novartis. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Creditor Lumina Said to Mull Selling Debt in HIG's Kora Saude
Creditor Lumina Said to Mull Selling Debt in HIG's Kora Saude

Bloomberg

time16 minutes ago

  • Bloomberg

Creditor Lumina Said to Mull Selling Debt in HIG's Kora Saude

Investment firm Lumina Capital Management is weighing a debt sale tied to Brazilian health-care company Kora Saude Participações SA less than a year after acquiring a chunk of the company's local notes, according to people familiar with the matter. Lumina has held talks with potential buyers, the people said, asking not to be named discussing private details. The deal is dependent on Kora raising equity, which would increase the appeal for the company's local debt, one of the people said.

Nike Co-Founder Phil Knight Gives $2 Billion to Oregon Cancer Center in Record Gift
Nike Co-Founder Phil Knight Gives $2 Billion to Oregon Cancer Center in Record Gift

Wall Street Journal

time16 minutes ago

  • Wall Street Journal

Nike Co-Founder Phil Knight Gives $2 Billion to Oregon Cancer Center in Record Gift

Nike co-founder Phil Knight and his wife, Penny, are donating $2 billion to Oregon Health & Science University's Knight Cancer Institute—the largest known single gift to a U.S. university, coming at a time when colleges' public funding is under siege. The gift will roughly double the size of the cancer center, expanding its capacity to treat patients and conduct research.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store